Novel diagnostic assay for gastric and gastroesophageal junction cancer receives CE Mark approval
Roche obtains CE certification for VENTANA CLDN18 (43-14A) RxDx Assay to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY